PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Beubstitute for form 1449A/PTO Complete if Known 10/516,587 Application Number INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 1

Sheet

Filing Date December 3, 2004 Akiko NISHI, et al First Named Inventor Art Unit Unassigned Unassigned Examiner Name 12218/42 Attorney Docket Number

•			U.S. PATEN	T DOCUME	ENTS			
Examiner Initials *	Cita	Document Number	Publication Date	Name o	of Patentee or Applicant of C	ited Pages Columns Lines Wh	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	Cite No. <sup>6</sup>	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY		Document	Passages or Relev		
m	1	US 5,168,048	08-18-1992	2	Quax			
		F	OREIGN PAT	ENT DOCU	MENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines,		
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)		MM-DD-YYYY		Where Relevant Passages or Relevant Figures Appear	Τ <sup>6</sup>	
W	2	JP 4-228073		12-01-1992	GIST BROCADES NV INL1	Corresponds to US 5,168,048	AB:	
NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							Т,	
W	3	Crowder, Michael, W., et al., "Overexpression, Purification, and Characterization of the Cloned Metallo-\(\beta\)-Lactamase L1 from Stenotrophomonas maltophilia, Antimicrobial Agents and Chemotherapy, Vol. 42, No. 4, Apr. 1998, p. 921-926.						
M	4	Hernández-Jústiz, O., et al., "Evaluation of different enzymes as catalysts for the production of β-lactam antibiotics following a kinetically controlled strategy, Enzyme and Microbial Technology 25, April 1999, p. 336-343.						
Examiner Signature		Maliches		Date Consid	ered 0	2/02/06		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-